Literature DB >> 8412015

Non-ketotic hyperglycinaemia: molecular lesion, diagnosis and pathophysiology.

K Tada1, S Kure.   

Abstract

Non-ketotic hyperglycinaemia (NKH) is a well-recognized metabolic cause of life-threatening illness in the neonate. The fundamental defect is in the glycine cleavage system, which consists of four protein components. Our study revealed that the majority of NKH patients had a specific defect in P-protein (glycine decarboxylase). The primary lesion of NKH at gene level was investigated, using cDNA encoding human glycine decarboxylase. A three-base deletion resulting in deletion of Phe756 was found in a Japanese patient with NKH. The majority of NKH patients in Finland, where there is a high incidence of NKH, were found to be due to a common mutation, a point mutation resulting in the amino acid substitution of Ile564 for Ser564. Prenatal diagnosis is feasible by determining the activity of the glycine cleavage system and is also possible by DNA analysis. Recent findings suggest that a high concentration of glycine in the brain may contribute to the pathophysiology of NKH by overactivating N-methyl-D-aspartate receptors allosterically, which may result in intracellular calcium accumulation, DNA fragmentation and neuronal death. These provide the possibility that early treatment with N-methyl-D-aspartate receptor antagonist may prevent brain damage in NKH.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8412015     DOI: 10.1007/bf00711901

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  27 in total

1.  Regional distribution and properties of the glycine cleavage system within the central nervous system of the rat: evidence for an endogenous inhibitor during in vitro assay.

Authors:  E C Daly; N S Nadi; M H Aprison
Journal:  J Neurochem       Date:  1976-01       Impact factor: 5.372

2.  Prenatal diagnosis of nonketotic hyperglycinemia: enzymatic analysis of the glycine cleavage system in chorionic villi.

Authors:  K Hayasaka; K Tada; N Fueki; J Aikawa
Journal:  J Pediatr       Date:  1990-03       Impact factor: 4.406

3.  Feasibility of prenatal diagnosis of nonketotic hyperglycinemia: existence of the glycine cleavage system in placenta.

Authors:  K Hayasaka; K Tada; N Fueki; I Takahashi; A Igarashi; T Takabayashi; R Baumgartner
Journal:  J Pediatr       Date:  1987-01       Impact factor: 4.406

Review 4.  The glycine cleavage system: composition, reaction mechanism, and physiological significance.

Authors:  G Kikuchi
Journal:  Mol Cell Biochem       Date:  1973-06-27       Impact factor: 3.396

5.  Hyperglycinemia: a defect in glycine cleavage reaction.

Authors:  K Tada; K Narisawa; T Yoshida; T Konno; Y Yokoyama
Journal:  Tohoku J Exp Med       Date:  1969-07       Impact factor: 1.848

6.  Glutamate triggers internucleosomal DNA cleavage in neuronal cells.

Authors:  S Kure; T Tominaga; T Yoshimoto; K Tada; K Narisawa
Journal:  Biochem Biophys Res Commun       Date:  1991-08-30       Impact factor: 3.575

Review 7.  Non-ketotic hyperglycinemia: a life-threatening disorder in the neonate.

Authors:  K Tada; S Kure; M Takayanagi; A Kume; K Narisawa
Journal:  Early Hum Dev       Date:  1992 Jun-Jul       Impact factor: 2.079

8.  Amino acid sequence of the phosphopyridoxyl peptide from P-protein of the chicken liver glycine cleavage system.

Authors:  K Fujiwara; K Okamura-Ikeda; Y Motokawa
Journal:  Biochem Biophys Res Commun       Date:  1987-12-16       Impact factor: 3.575

9.  Nonketotic hyperglycinemia: clinical and metabolic aspects.

Authors:  K Tada
Journal:  Enzyme       Date:  1987

10.  Nonketotic hyperglycinemia: treatment with NMDA antagonist and consideration of neuropathogenesis.

Authors:  Y Ohya; N Ochi; N Mizutani; C Hayakawa; K Watanabe
Journal:  Pediatr Neurol       Date:  1991 Jan-Feb       Impact factor: 3.372

View more
  12 in total

Review 1.  The Finnish Disease Heritage III: the individual diseases.

Authors:  Reijo Norio
Journal:  Hum Genet       Date:  2003-03-08       Impact factor: 4.132

2.  Prediction of long-term outcome in glycine encephalopathy: a clinical survey.

Authors:  Julia B Hennermann; Jeanne-Marie Berger; Ulrike Grieben; Gunter Scharer; Johan L K Van Hove
Journal:  J Inherit Metab Dis       Date:  2011-10-15       Impact factor: 4.982

3.  [Clinical and molecular genetic characteristics of nonketotic hyperglycinemia].

Authors:  Hai-Feng Li
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-03

4.  Pulmonary hypertension associated with nonketotic hyperglycinaemia.

Authors:  S Cataltepe; L J van Marter; H Kozakewich; D L Wessel; P J Lee; H L Levy
Journal:  J Inherit Metab Dis       Date:  2000-03       Impact factor: 4.982

5.  Structure of P-protein of the glycine cleavage system: implications for nonketotic hyperglycinemia.

Authors:  Tadashi Nakai; Noriko Nakagawa; Nobuko Maoka; Ryoji Masui; Seiki Kuramitsu; Nobuo Kamiya
Journal:  EMBO J       Date:  2005-03-24       Impact factor: 11.598

6.  Perioperative care of a child with non-ketotic hyperglycinemia.

Authors:  Joy Allee; Joseph D Tobias
Journal:  Saudi J Anaesth       Date:  2010-09

Review 7.  Glycine and hyperammonemia: potential target for the treatment of hepatic encephalopathy.

Authors:  Rune Gangsøy Kristiansen; Christopher F Rose; Lars Marius Ytrebø
Journal:  Metab Brain Dis       Date:  2016-06-23       Impact factor: 3.584

Review 8.  Metabolism of amino acid neurotransmitters: the synaptic disorder underlying inherited metabolic diseases.

Authors:  Stefan Kölker
Journal:  J Inherit Metab Dis       Date:  2018-06-04       Impact factor: 4.982

Review 9.  Enzymes in Metabolic Anticancer Therapy.

Authors:  Maristella Maggi; Claudia Scotti
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

10.  Biochemical and computational approaches to improve the clinical treatment of dopa decarboxylase-related diseases: an overview.

Authors:  Barbara Cellini; Riccardo Montioli; Elisa Oppici; Carla Borri Voltattorni
Journal:  Open Biochem J       Date:  2012-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.